Please login to the form below

Not currently logged in
Email:
Password:

Spectrum appoints chief medical officer

Lee Allen joins from AMAG Pharmaceuticals

Lee Allen, SpectrumDr Lee Allen has joined cancer-focused Spectrum Pharmaceuticals as chief medical officer.

Dr Allen will lead the development of the US-based biotech's pipeline of products, including its investigational cancer drug belinostat, which is due to be filed for approval in mid-2013.

The appointment is a return to oncology for Dr Allen following a six-year spell as chief medical officer at AMAG Pharmaceuticals – the developer of Feraheme (ferumoxytol) for the treatment of iron deficiency anaemia in adult patients with chronic kidney disease.

Prior to this period, he spent four years at Wyeth from 2003 to 2007, serving as VP of clinical R&D for oncology.

Earlier in his career, he also spent time as executive director, site therapeutic area leader for oncology at Pfizer and medical director of oncology and immunology at BASF's Knoll Pharmaceuticals.

"I am very excited to join Spectrum, which I believe has a very promising portfolio of late-stage compounds," said Dr Allen.

"The company has the prospect of being able to introduce two to three new anti-cancer products by 2015 or 2016.”

Dr Allen's predecessor as chief medical officer, Dr Steve Fruchtman, will remain at Spectrum in the newly created role of senior VP, haematology and oncology R&D.

19th March 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...